Abbott Laboratories (ABT)

64.75
NYSE : Health Technology
Prev Close 64.75
Day Low/High 0.00 / 0.00
52 Wk Low/High 48.05 / 65.50
Avg Volume 5.18M
Exchange NYSE
Shares Outstanding 1.75B
Market Cap 110.10B
EPS 0.30
P/E Ratio 299.05
Div & Yield 1.12 (1.76%)

Latest News

Abbott Labs Fired on All Cylinders In the Second Quarter

The company is on track for another terrific year of double digit earnings per share growth.

Abbott Shares Rise on Second-Quarter Beat, Increased Guidance

Abbott Shares Rise on Second-Quarter Beat, Increased Guidance

The Abbott Park, Ill., healthcare company beats top- and bottom-line estimates and raises its full-year outlook for earnings.

Here Are 6 Chip Stocks That I Like Better Than Texas Instruments: Market Recon

Here Are 6 Chip Stocks That I Like Better Than Texas Instruments: Market Recon

This group is expected to post second-quarter EPS gains of 30%; here is how to trade it.

Abbott Reports Second-Quarter 2018 Results

Abbott Reports Second-Quarter 2018 Results

- Second-quarter reported sales growth of 17.0 percent; GAAP EPS from continuing operations of $0.40

Google, Morgan Stanley, IBM and Texas Instruments - 5 Things You Must Know

Google, Morgan Stanley, IBM and Texas Instruments - 5 Things You Must Know

U.S. stock futures are flat on Wednesday, following an upbeat assessment of the U.S. economy from Federal Reserve Chairman Jerome Powell; Morgan Stanley and IBM report earnings; Google faces a record $5 billion fine from the European Union.

Abbott's Capital Flexibility in Focus Ahead of Earnings Release

Abbott's Capital Flexibility in Focus Ahead of Earnings Release

In April, CEO Miles White said the healthcare company had paid down $6 billion of debt this year and expected to pay down another $2 billion by the end of 2018.

Stocks Shake Off Trade War Fears

U.S. stocks ended the week higher as earnings season got underway and investors shook off the latest round of trade tensions

Abbott Receives FDA Approval For Next-Generation MitraClip® Device To Treat People With Leaky Heart Valves

Abbott Receives FDA Approval For Next-Generation MitraClip® Device To Treat People With Leaky Heart Valves

- Innovations designed to allow doctors to treat more types of cases and anatomies - MitraClip is the gold-standard minimally invasive alternative to open-heart surgery for people needing mitral valve repair - Mitral regurgitation, the most common heart...

Abbott Announces Freedom 2 Save Program For Employees To Address Student Debt

Abbott Announces Freedom 2 Save Program For Employees To Address Student Debt

- Two-Thirds of Millennials Aren't Saving for Retirement

New Late-Breaking Data At ADA Underscore Significant Benefits Of Abbott's FreeStyle Libre System For People Living With Diabetes

New Late-Breaking Data At ADA Underscore Significant Benefits Of Abbott's FreeStyle Libre System For People Living With Diabetes

- Expanded Real-World Evidence from More than 250,000 individuals using Freestyle libre system Showed Higher Frequency Scanning is Associated with improved glucose control, decreased glucose variability and reduced incidence of both daytime and nocturnal hypoglycemia

Weekly Roundup

Markets had a tumultuous week starting with increased trade war fears and ending with a modest oil production increase from OPEC.

Abbott Hosts Conference Call For Second-Quarter Earnings

Abbott Hosts Conference Call For Second-Quarter Earnings

ABBOTT PARK, Ill., June 20, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2018 financial results on Wednesday, July 18, 2018, before the market opens.

Weekly Roundup

Rate hikes and trade wars weighed on stocks this week.

How to Handle the Fed: Cramer's 'Mad Money' Recap (Wednesday 6/13/18)

How to Handle the Fed: Cramer's 'Mad Money' Recap (Wednesday 6/13/18)

Jim Cramer says higher rates always trigger rotations. Here's what investors should expect.

Weekly Roundup

Markets bathed in the afterglow of the strong jobs report for most of the week.

Abbott Declares 378th Consecutive Quarterly Dividend

Abbott Declares 378th Consecutive Quarterly Dividend

ABBOTT PARK, Ill., June 8, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 28 cents per share.

100 Stocks That Could Change Your Financial Future

100 Stocks That Could Change Your Financial Future

Looking for good stock ideas? TheStreet has you covered with a plethora of names gleaned from our readings.

Weekly Roundup

Markets go through a short and volatile week.

Abbott Introduces The Afinion™ 2 Analyzer Rapid Test System For Diabetes Management

STATE-OF-THE-ART MULTI-ASSAY TEST SYSTEM HELPS PEOPLE WITH DIABETES GET THE HbA1c RESULTS THEY NEED WITHIN 3 MINUTES -- ALLOWING MORE TIME FOR CONSULTATION AND CARE DURING A SINGLE HEALTHCARE VISIT

Jim Cramer's List of 88 Stocks to Watch With Interest Rates Falling Again

Jim Cramer's List of 88 Stocks to Watch With Interest Rates Falling Again

The Memorial Day holiday is now over, and it's time for investors to get back to work looking for top stocks. TheStreet's founder Jim Cramer has a must watch list.

Medical Device Stocks Could Be Gearing Up to Be Market Leaders

Medical Device Stocks Could Be Gearing Up to Be Market Leaders

When chartists look for the next market leaders they often go to stocks that have held up the best during corrections.

Jim Cramer: When Rates Decline, 96% of the S&P 500 Benefits

Jim Cramer: When Rates Decline, 96% of the S&P 500 Benefits

When rates decline, most of the S&P 500 benefits, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.

Jim Cramer: Stocks That Do Well In a Declining Rate Environment Are Back

Jim Cramer: Stocks That Do Well In a Declining Rate Environment Are Back

The crash of oil will only accelerate the move.

Weekly Roundup

China trade wars, North Korea tensions and oil volatility hit the markets this week.

Abbott Laboratories Takes Over #38 Spot From NextEra Energy

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Abbott Laboratories has taken over the #38 spot from NextEra Energy Inc , according to ETF Channel. Below is a chart of Abbott Laboratories versus NextEra Energy Inc plotting their respective rank within the S&P 500 over time (ABT plotted in blue; NEE plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

Newest Generation Of Leading Heart Stent Is Now Approved In The U.S. For People With Coronary Artery Disease

- XIENCE Sierra™, the newest generation of XIENCE drug-eluting stents, received U.S. Food and Drug Administration (FDA) approval

Abbott's Investigational Tendyne™ Device For Mitral Valve Replacement Demonstrates Positive Outcomes At 30 Days In Global Study

- Promising results for Tendyne valve presented as late-breaking clinical trial at EuroPCR

Updates on Honeywell, Abbot and Nvidia

Conference highlights from Honeywell bolster the investment case.

TheStreet Quant Rating: B- (Buy)